Medicine Recommendations

In combination therapy for treating type 2 diabetes (NICE TA288)

NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Treating chronic heart failure with preserved or mildly reduced ejection fraction (NICE TA902)

NICE TA 902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

Monotherapy for treating type 2 diabetes (NICE TA390)

NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

NICE TA679 - for treating chronic heart failure with reduced ejection fraction

Treatment of premature ejaculation (PE) in men 18-64 years of age

Treating long-term insomnia (NICE TA922)

NICE TA922 - Daridorexant for treating long-term insomnia

Urinary frequency, urgency, and incontinence

Darvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)

NICE TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn’s disease

Suppression of inflammatory and allergic disorders

treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases

Degarelix for treating advanced hormone-dependent prostate cancer (NICE TA404)

Hyponatraemia

Denosumab for treatment of Glucocorticoid-induced osteoporosis

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Prevention of osteoporotic fractures in men

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Prevention of osteoporotic fractures in postmenopausal women (NICE TA204)

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE TA265)

NICE TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours 

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate

MHRA Drug Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

Deucravacitinib for treating moderate to severe plaque psoriasis

NICE TA 907 - Deucravacitinib for treating moderate to severe plaque psoriasis

Bowel obstruction - reduction of tumour oedema associated with bowel obstruction

Breathlessness

Corticosteroids in palliative care - Anorexia, Adjuvant analgesic, Nausea and vomiting associated with chemotherapy, Obstructive syndromes, Raised intracranial pressure, Spinal cord compression

Nausea and vomiting - raised Intracranial Pressure

Palliative care emergencies - SVC obstruction AND Metastatic spinal cord compression

Macular Oedema - retinal vein occlusion (NICE TA229)

Treating non-infectious uveitis (NICE TA460)